CombiGene AB, a gene therapy company, has signed an agreement with the CDMO Cobra Biologics for the production of drug candidate CG01 for early clinical trials. The agreement with Cobra consists of three separate contracts that will be undertaken, specifically quality, production of plasmids and production of CG01.    The Master Service Agreement includes manufacturing of CG01 for clinical studies as well as commercial production upon approval. CombiGene will pay Cobra approximately SEK 1.5 mi...